相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Natural products as LSD1 inhibitors for cancer therapy
Yuan Fang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Evangelos Eleutherakis-Papaiakovou et al.
JOURNAL OF ONCOLOGY (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
Mehmet Baysal et al.
SCIENTIFIC REPORTS (2020)
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Flavia Alves Verza et al.
CANCERS (2020)
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
Todd M. Bauer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Yuan Fang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
A. Ray et al.
LEUKEMIA (2018)
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Tamara Maes et al.
CANCER CELL (2018)
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ibraheem Ali et al.
CHEMICAL REVIEWS (2018)
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Xiu-Xiu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Jay H. Kalin et al.
NATURE COMMUNICATIONS (2018)
Histone deacetylase 6 in cancer
Ting Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment
Ying-Chao Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Advances toward LSD1 inhibitors for cancer therapy
Xiaoli Fu et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice
Rajinish Kumar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew J. Yee et al.
LANCET ONCOLOGY (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
Melissa M. Singh et al.
NEURO-ONCOLOGY (2015)
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W. Fiskus et al.
LEUKEMIA (2014)
Salvage Therapy of Multiple Myeloma: The New Generation Drugs
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells
Shauna N. Vasilatos et al.
CARCINOGENESIS (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells
Yi Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2
Claudia Binda et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 Å
Shinya Mimasu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine
Maojun Yang et al.
BIOCHEMISTRY (2007)
分享论文
